Savara, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Savara is in Stage 4, the downtrend phase, now in week 6 (since Sep 11, 2026). It closed at $4.54, 34.6% below its 52-week high and below its 200-day average, which is falling.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. More about the company

$4.54

-3.98% today

$933M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SVRA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 20w

S4 29w

S2 24w

S3 19w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 10w → S3 7w → S2 20w → S3 9w → S4 8w → S1 5w → S4 29w → S1 7w → S4 10w → S1 3w → S2 24w → S3 19w → S2 9w → S4 6w current

Total tracked: 165 weeks across 14 stage runs.

SVRA among Biotechnology160th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…160	SVRASavara, Inc.	Stage 4 · wk 6	60	−9.2%

vs 52W High

-34.6%

$3.95 lo$6.94 hi

34.6% below 52W high, ongoing decline

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-16.3%

200 DMA: $5.42 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.36x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-9.2%

-17.6%

-8.1%

YTD

-19.5%

+7.3%

Scan Membership

Breakout Watch

Latest: 2023-12-12

8 appearances in last 60 days. First seen: 2019-05-14.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 1.36x

2026-10-21S4

Wk 6 · Vol 0.90x

2026-10-20S4

Wk 6 · Vol 2.30x

2026-10-19S4

Wk 6 · Vol 0.81x

2026-10-16S4

Wk 6 · Vol 1.18x

2026-10-15S4

Wk 5 · Vol 0.89x

2026-10-14S4

Wk 5 · Vol 1.37x

2026-10-13S4

Wk 5 · Vol 2.04x

2026-10-12S4

Wk 5 · Vol 0.71x

2026-10-09S4

Wk 5 · Vol 0.84x

2026-10-08S4

Wk 4 · Vol 1.40x

2026-10-07S4

Wk 4 · Vol 1.35x

Moving averages & range

50 DMA

$5.16

200 DMA

$5.42

52W High

$6.94

52W Low

$3.95

5D Low

$4.45

Resistance levels (recent highs)

20d High

$5.16

60d High

$5.83

120d High

$6.38

250d High

$6.94

Next resistance

+13.7%

to 20d High

ROE

-105.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 8.0

Savara: quick answers

What stage is Savara in?

As of Oct 22, 2026, Savara (SVRA) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 11, 2026 and is in week 6. What the four stages mean

Is Savara in an uptrend?

No. Savara is in a Stage 4 downtrend. It trades 16.3% below its 200-day average, which is falling.

How far is Savara from its 52-week high?

Savara closed at $4.54 on Oct 22, 2026, 34.6% below its 52-week high of $6.94. Its 52-week low is $3.95.

How has Savara performed over the past year?

As of Oct 22, 2026, Savara is up 7.3% over the past year and down 19.5% so far in 2026.

Which sector and industry is Savara in?

Savara is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.